Weight loss achieved with GLP-1–based antiobesity medications alters fat-free mass and skeletal muscle mass, raising questions about functional outcomes.
Reductions in skeletal muscle mass during therapeutic weight loss may influence subsequent weight regain and long-term metabolic health in obesity.
Assessment of body composition changes highlights the need to evaluate whether preserving fat-free mass improves clinical outcomes in people with obesity.
Abstract
This Viewpoint explores the effects of weight loss achieved through GLP-1–based antiobesity medications on weight regain, fat-free mass, and skeletal muscle mass in people with obesity.